Condition: Atrial Fibrillation (AF) · Sponsor: German Heart Institute
This pilot study investigates if non-invasive global mapping can guide catheter ablation of atrial fibrillation (AF) by defining personalized targets based on the temporal Stability of local Atrial High-Rate Activity (SAHRA). The study also assesses efficacy and safety of this approach and evaluates potential signals of harm. The main questions it aims to answer are: * Does ablation of targets defined by non-invasive global mapping improve rates of acute atrial fibrillation termination? * Does such a personalized ablation approach reduce arrhythmia recurrence rates? Researchers will compare the results of the personalized ablation approach with comparable patients that had undergone a conventional "empirical" ablation approach (pulmonary vein isolation). Participants will: * Undergo a personalized catheter ablation approach employing both a non-invasive global mapping system and a conventional intracardiac mapping system * Visit the clinic 3, 6 and 12 months after ablation for clinical follow-up * Schedule a telephone visit 9 and 24 months after ablation for clinical follow-up
This description comes directly from the study's public registry record.
Till F Althoff, M.D. · 0049 30 450613163 · till.althoff@dhzc-charite.de
Gerhard Hindricks, M.D. · 030450613163 · gerhard.hindricks@dhzc-charite.de
Always discuss trial participation with your own doctor first.
| German Heart Center of the Charité, Charité University Hospital Berlin | Berlin, Germany | Recruiting |
| Frankfurt University Heart and Vascular Center | Frankfurt am Main, Germany | Not Yet Recruiting |
| Central Lisbon University Hospital Centre (CHULC), Hospital de Santa Marta | Lisbon, Portugal | Not Yet Recruiting |
| Hospital Clinic, University of Barcelona | Barcelona, Spain | Not Yet Recruiting |
| Gregorio Marañón General University Hospital | Madrid, Spain | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07320560